News $40bn Teva generic deal awaits antitrust approval Acquisition of Allergan's generics business ready.
News Impax buys Teva and Allergan generics for $586 million Teva must sell some assets before buying Allergan's generics business.
News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
Articles Teva: looking for innovation and growth in ‘space between’ b... Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
